BMS-734016
Showing 26 - 50 of 996
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Houston
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Ipilimumab
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
- Ipilimumab
- Nivolumab
-
Rochester, MinnesotaMayo Clinic in Rochester
May 6, 2022
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium
Active, not recruiting
- Advanced Renal Cell Carcinoma
- +5 more
- Clostridium butyricum CBM 588 Probiotic Strain
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 12, 2022
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial in Duarte
Recruiting
- Clear Cell Renal Cell Carcinoma
- +3 more
- Biospecimen Collection
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 19, 2023
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Trial in Baltimore (Ipilimumab, Nivolumab,
Completed
- Prostate Cancer
- +2 more
- Ipilimumab
- +2 more
-
Baltimore, MarylandJohns Hopkins University/Sidney Kimmel Cancer Center
Jan 6, 2022
Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)
Recruiting
- Advanced Cancer
- Relatlimab
- +3 more
-
Duarte, California
- +23 more
Oct 24, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Atlanta (VX15/2503, Ipilimumab, Nivolumab)
Recruiting
- Squamous Cell Carcinoma of the Head and Neck
- VX15/2503
- +2 more
-
Atlanta, GeorgiaEmory University Hospital Midtown
Mar 2, 2022
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Ipilimumab
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Feb 11, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Tumor in the Brain Trial in
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +6 more
- Ipilimumab
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 12, 2022
Advanced Malignant Solid Tumor, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung Trial in Houston (drug,
Recruiting
- Advanced Malignant Solid Neoplasm
- +4 more
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 30, 2021
Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial
Recruiting
- Advanced Malignant Solid Neoplasm
- +8 more
- Imatinib Mesylate
- Ipilimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 1, 2022
Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma Trial in
Active, not recruiting
- Dedifferentiated Liposarcoma
- +5 more
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Metastatic Malignant Solid Neoplasm
- +3 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
Bethesda, Maryland
- +4 more
Aug 16, 2022
Melanoma Stage Iv, Melanoma Stage Iii, Melanoma Trial in Australia (Denosumab, Nivolumab, Ipilimumab)
Active, not recruiting
- Melanoma Stage Iv
- +2 more
- Denosumab
- +2 more
-
Albury, New South Wales, Australia
- +9 more
Apr 6, 2022
Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in
Recruiting
- Recurrent Endometrial Adenocarcinoma
- +8 more
- Ipilimumab
- Nivolumab
-
Iowa City, Iowa
- +9 more
Jan 27, 2023
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma
Recruiting
- Clinical Stage I Cutaneous Melanoma AJCC v8
- +8 more
- Ipilimumab
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 28, 2022
Diffuse Hemispheric Glioma, H3 G34-Mutant Trial in Los Angeles (biological, procedure, drug)
Not yet recruiting
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Dendritic Cell Tumor Peptide Vaccine
- +6 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jul 13, 2022
Malignant Melanoma Trial in United States (BMS-936558 (MDX1106-04), Ipilimumab)
Completed
- Malignant Melanoma
- BMS-936558 (MDX1106-04)
- Ipilimumab
-
New Haven, Connecticut
- +3 more
Mar 19, 2021
Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+
Active, not recruiting
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma
- Aldesleukin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma Trial in
Not yet recruiting
- BCLC Stage B Hepatocellular Carcinoma
- +10 more
- Ipilimumab
- Nivolumab
-
Miami, Florida
- +4 more
Aug 23, 2022
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Trial in United States
Recruiting
- Metastatic Renal Cell Carcinoma
- +3 more
- Avelumab
- +7 more
-
Danville, Illinois
- +4 more
Jul 29, 2022